HC Wainwright set a $5.00 target price on Protalix Biotherapeutics (NYSEAMERICAN:PLX) in a report released on Wednesday, March 14th. The firm currently has a buy rating on the stock.
A number of other research analysts also recently commented on the stock. Zacks Investment Research downgraded shares of Protalix Biotherapeutics from a hold rating to a sell rating in a report on Saturday, March 10th. BidaskClub downgraded shares of Protalix Biotherapeutics from a sell rating to a strong sell rating in a report on Saturday, December 2nd.
PLX stock traded up $0.01 during trading on Wednesday, reaching $0.46. The company’s stock had a trading volume of 732,533 shares, compared to its average volume of 907,554. Protalix Biotherapeutics has a 1 year low of $0.42 and a 1 year high of $1.40.
Protalix Biotherapeutics (NYSEAMERICAN:PLX) last issued its quarterly earnings results on Tuesday, March 6th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.06) by ($0.04). The business had revenue of $2.47 million during the quarter, compared to analyst estimates of $9.70 million.
A hedge fund recently bought a new stake in Protalix Biotherapeutics stock. Opaleye Management Inc. acquired a new stake in shares of Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 1,825,000 shares of the company’s stock, valued at approximately $1,206,000. Opaleye Management Inc. owned 1.27% of Protalix Biotherapeutics as of its most recent SEC filing.
COPYRIGHT VIOLATION NOTICE: “Protalix Biotherapeutics (PLX) Given a $5.00 Price Target by HC Wainwright Analysts” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States and international trademark & copyright laws. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/04/08/hc-wainwright-analysts-give-protalix-biotherapeutics-plx-a-5-00-price-target.html.
About Protalix Biotherapeutics
Protalix BioTherapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers taliglucerase alfa for injection, which is an enzyme replacement therapy for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease.
Receive News & Ratings for Protalix Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.